NA Proactive news snapshot: NexTech AR, Nano One Materials, Mindset Pharma, Los Andes Copper, Algernon Pharmaceuticals...

NexTech AR Solutions Corp (OTCQB:NEXCF) (CSE:NTAR) (NEO:NTAR) (FRA:N29) has launched EdTechX, a versatile virtual education solution built on Microsoft Azure. EdTechX combines enterprise-scale video streaming, integrated assessments, augmented reality holograms and data analytics, enabling educational institutions to transform traditional learning and event formats into valuable digital experiences. 

Nano One Materials Corp (CVE:NNO) (OTCPINK:NNOMF) (FRA:LBMB) has strengthened its business relationship with materials and chemicals giant Johnson Matthey PLC (LON:JMAT) (OTCMKTS:JMPLF) (FRA:JMT2), signing a joint development deal to advance lithium-ion battery materials. Under the agreement, the companies will co-develop next-generation products and processes for Johnson Matthey’s (JM) eLNO group of nickel-rich advanced cathode materials using Nano One’s patented One-Pot process. The work will lead to a detailed commercialization study for pre-pilot, pilot and scaled-up manufacturing.

Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) has selected next-generation psychedelic compound MSP-1014 as its lead clinical candidate. In a statement, the company said the differentiated psilocybin-based compound will move forward into current good manufacturing practice (cGMP) compliant manufacturing and investigational new drug (IND)-enabling studies. MSP-1014 demonstrated superior preclinical characteristics in a head-to-head comparison with psilocybin and its active metabolite psilocin, including increased safety and efficacy, which the company believes will potentially result in lower clinical doses. 

Los Andes Copper Ltd (CVE:LA) (OTCMKTS:LSANF) (FRA:L41A) said the previously announced US$5 million convertible debenture investment from Queen’s Road Capital Investment Ltd (CVE:QRC) was now complete. The proceeds will go towards completing the pre-feasibility study for the company’s Vizcachitas copper project in Chile. The convertible debenture has a five-year term, carries an 8% coupon, and will be convertible into common shares in Los Andes at C$10.82 each. The interest is payable quarterly, 5% in cash and 3% in shares, at the 20-day volume-weighted average price prior to the interest payment date.

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) is expanding its investigation into the use of Ifenprodil in pancreatic cancer with a new clinical research program. Previous studies have indicated that Idenprodil (NP-120) demonstrated a significant anti-tumour effect in a pancreatic cancer animal model. A recent research paper published in the Dove Press Journal, Clinical Pharmacology: Advances and Applications concluded that Ifenprodil “significantly and rapidly” reduced the average solid tumour size by nearly 50% after three days, and remained stable while on treatment in a murine model of pancreatic cancer.

HempFusion Wellness Inc (TSE:CBD.U) (OTCQX:CBDHF) (FRA:8OO) announced it has officially launched its Private Label division after receiving a 10 stock keeping unit (SKU) private label deal with a publicly-traded US national grocery retailer. The company said the initial order is for about $250,000 and is scheduled to ship in July 2021. 

Fobi AI Inc (CVE:MTRX) (OTCQB:RACMF) announced that the TSX Venture Exchange has approved its proposed name change from Loop Insights Inc and trading symbol change from MTRX to FOBI. Trading under the new symbol will start at the opening of the market on Friday, the company said.

Biocept Inc (NASDAQ:BIOC) (FRA:B003) said Michael Nall, president and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3pm EST (12pm PT). “We look forward to providing investors with an update on CNSide, our novel assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system,” said Nall. “CNSide’s full commercial launch is now underway with the potential to provide critical information for the approximately 200,000 patients in the U.S. each year who have progression of their cancer to the central nervous system.” The company said investors and other interested parties can register before Biocept’s presentation HERE. Following the presentation, the webcast will be available on the company’s website for 90 days.

Pacific Empire Minerals Corp (CVE:PEMC) (OTCQB:PEMSF) (FRA:1YK) said it has closed the second and final tranche of an oversubscribed non-brokered private placement for gross proceeds of around $289,999, taking the total proceeds from the first and second tranches to around $1.27 million. The copper explorer said it issued around 4.83 million units at a price of $0.06 each in the second tranche, each of which consists of one share and one share purchase warrant with an exercise price of $0.10 each for 24 months from the closing of the offering. 

Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) said it has contracted dacs Marketing, a full-service ad agency, to build its brand and marketing strategy as it moves to commercialize its mushroom-derived products and associated consumer packaged goods. ”This is an important step for the company as we initiate plans to commercialize our products in the first half of 2022. Identifying dacs as an agency that understands the health and wellness category, as well as the alternative categories including psychedelics and cannabis, is key to helping Psyched build a fulsome go-to-market strategy,” Psyched chief executive Jeff Stevens said in a statement. 

CleanSpark Inc (NASDAQ:CLSK) said it has extended and expanded a contract manufacturing agreement with Pioneer Power Solutions Inc (NASDAQ:PPSI) through to the end of 2023. The software, services, and clean Bitcoin mining firm said as part of the new agreement, Pioneer Power has been granted expanded rights to utilize CleanSpark’s proprietary software products, including mPulse and GridFabric’s OpenADR solutions. The company added that Pioneer plans to bundle the solutions with PowerBloc, PPSI’s integrated charging and power solution for electric vehicle (EV) infrastructure. CleanSpark also said it has been granted expanded rights and opportunities to serve as a preferred distributor of the PowerBloc solution.

Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1), the biopharma focused on hard pill cannabis formulations, said it had received C$1,259,250 gross from the early exercise of warrants. The 1,679,000 warrants were issued in the final week of May and were each exercised into one common company share at C$0.75. The warrants had been set to expire in late February or early March of 2022. ”We are pleased to receive this vote of confidence from our longstanding loyal shareholders, who have voluntarily exercised their warrants long before expiry to further solidify the company’s treasury as we continue to press forward on our sales, production and delivery of product. We would like to thank those shareholders that continue to believe and support Canntab,” said Canntab’s CEO Larry Latowsky in a statement.

Story by ProactiveInvestors